Sanofi SA vs Western Digital Corp — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Western Digital Corp trades at $476.52 (market cap $172.09B). The key difference: Western Digital Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | WDC | |
|---|---|---|
Market Cap | $104.06B | $172.09B |
Sector | Health | Technology |
52-Week High | $52.34 | $746.23 |
52-Week Low | $41.33 | $95.03 |
Enterprise Value | $124.09B | $171.56B |
Dividend Yield | 5.61% | 0.13% |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Western Digital (WDC) trades at $477.30, up 2.1% on the day, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a net income margin of 71.97% and ROE of 131.02%, supported by positive cash flow trends. Recent news highlights AI-driven storage demand and institutional accumulation, such as CalSTRS increasing its stake by 64,424.3% in Q2 2026 (SEC filing, September 7, 2026).
Outlook remains favorable with a consensus price target of $676.70 (72% buy ratings), though risks include high valuation multiples and cyclical industry exposure. Earnings growth from AI data expansion is a key catalyst, but investor caution is warranted near all-time highs.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →